^
Association details:
| Biomarker: | WDR72 overexpression |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study
Published date:
11/30/2023
Excerpt:
This study aims to propose a new biomarker to predict the response to Nivolumab in patients with ccRCC....In all three checkmates, OS and progression free survival (PFS) were found to be significantly higher in WDR72 high expression group than that in WDR72 low expression group (P=0.040 and P=0.012, respectively), and similar conclusions could be drawn from the PBRM1-mutation (MUT) compared with the PBRM1-wildtype (WT) (P=0.007 and P=0.006, respectively).
DOI:
https://doi.org/10.18632/aging.205261
